ArticleInternational journal of women's health2026
Efficacy of Vaginal Misoprostol for Labor Induction in Intrauterine Fetal Death: A Cohort Study from West Java Largest Hospital.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the efficacy of vaginal misoprostol for labor induction in intrauterine fetal death (IUFD) at ≥20 weeks' gestation. Patients and Methods: This retrospective cohort study reviewed medical records of IUFD cases between 2021 and 2023 at Dr. Hasan Sadikin General Hospital, Bandung, Indonesia. Women with IUFD at ≥20 weeks' gestation who underwent vaginal misoprostol induction were included, and cases with incomplete key data were excluded. Outcomes included induction-to-contraction interval, induction-to-delivery interval, and cumulative misoprostol dose. Comparisons across gestational age groups (21-27, 28-36, and ≥37 weeks) were performed using the Kruskal-Wallis test; categorical variables were analyzed using the chi-square test. Results: Of 155 IUFD cases, 71 received misoprostol-only induction and were analyzed. Median induction-to-contraction intervals were 12 hours, 6 hours, and 3 hours in the 21-27, 28-36, and ≥37 weeks groups, respectively (p<0.001). Median induction-to-delivery intervals were 13 hours, 10 hours, and 6 hours, respectively (p=0.010). Median cumulative misoprostol doses decreased significantly with advancing gestational age: 200 µg, 100 µg, and 50 µg, respectively (p<0.001). Maternal age and parity did not differ significantly among groups. Conclusion: Vaginal misoprostol was associated with shorter induction intervals and lower cumulative dose requirements at later gestational ages in IUFD. Prospective multicenter studies are needed to confirm optimal regimens and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.